AURA
Aura Biosciences, Inc.$6.55-0.03 (-0.46%)Prev Close$6.58·MCap$360.4M·P/E—·Vol250.8K·Yield—
▲
Buys (12M)
2
$343.0K
▼
Sells (12M)
16
$1.02M
◆
Net Activity
Net Seller
$674.0K
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Aura Biosciences, Inc. (AURA) has been dominated by selling, with 2 insider purchases totaling $343.0K and 16 insider sales totaling $1.02M. The most recent insider transaction was by de los Pinos Elisabet (See Remarks), who sold $241.1K worth of shares on Feb 17, 2026. Aura Biosciences, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $360.4M.
AURA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | de los Pinos Elisabet | See Remarks | Sell | 47,648 | $5.06 | $241.1K | 0 |
| Feb 17, 2026 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 8,549 | $5.06 | $43.3K | 0 |
| Feb 17, 2026 | Hopkins Janet Jill | Chief Medical Officer | Sell | 20,401 | $5.06 | $103.2K | 0 |
| Feb 17, 2026 | Kilroy Conor | See Remarks | Sell | 12,079 | $5.05 | $61.0K | 0 |
| Feb 17, 2026 | Plavsic Mark | Chief Technology Officer | Sell | 15,890 | $5.05 | $80.2K | 0 |
| Jan 20, 2026 | de los Pinos Elisabet | See Remarks | Sell | 16,928 | $4.86 | $82.3K | 0 |
| Jan 20, 2026 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 1,581 | $4.86 | $7.7K | 0 |
| Nov 17, 2025 | Hopkins Janet Jill | Chief Medical Officer | Sell | 17,109 | $5.42 | $92.7K | 0 |
| Oct 29, 2025 | de los Pinos Elisabet | See Remarks | Sell | 9,049 | $6.35 | $57.5K | 0 |
| Oct 29, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 896 | $6.35 | $5.7K | 0 |
| Oct 16, 2025 | Plavsic Mark | Chief Technology Officer | Sell | 12,169 | $6.35 | $77.3K | 0 |
| Aug 18, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 7,722 | $6.70 | $51.7K | 0 |
| Jun 2, 2025 | de los Pinos Elisabet | See Remarks | Sell | 9,948 | $6.16 | $61.3K | 0 |
| May 16, 2025 | Gibney Anthony S | See Remarks | Buy | 50,000 | $4.90 | $245.0K | 0 |
| May 16, 2025 | Gibney Anthony S | See Remarks | Sell | 1,519 | $5.15 | $7.8K | 0 |
| May 16, 2025 | Johnson David Michael | Director | Buy | 20,000 | $4.90 | $98.0K | 0 |
| Apr 16, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 897 | $5.49 | $4.9K | 0 |
| Apr 16, 2025 | Kilroy Conor | See Remarks | Sell | 7,162 | $5.49 | $39.3K | 0 |
| Feb 18, 2025 | de los Pinos Elisabet | See Remarks | Sell | 20,221 | $7.75 | $156.8K | 0 |
| Feb 18, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 1,404 | $7.75 | $10.9K | 0 |
| Feb 18, 2025 | Hopkins Janet Jill | Chief Medical Officer | Sell | 2,534 | $7.75 | $19.6K | 0 |
| Feb 18, 2025 | Plavsic Mark | Chief Technology Officer | Sell | 2,151 | $7.75 | $16.7K | 0 |
| Jan 21, 2025 | de los Pinos Elisabet | See Remarks | Sell | 15,955 | $7.67 | $122.4K | 0 |
| Jan 21, 2025 | Elazzouzi Amy | Vice President, Finance | Sell | 1,001 | $7.67 | $7.7K | 0 |
| Nov 18, 2024 | Hopkins Janet Jill | Chief Medical Officer | Sell | 11,822 | $9.36 | $110.7K | 0 |
| Oct 29, 2024 | de los Pinos Elisabet | See Remarks | Sell | 9,200 | $10.74 | $98.8K | 0 |
| Oct 29, 2024 | Elazzouzi Amy | Vice President, Finance | Sell | 553 | $10.74 | $5.9K | 0 |
| Oct 18, 2024 | de los Pinos Elisabet | See Remarks | Sell | 24,992 | $12.04 | $300.8K | 0 |
| Oct 18, 2024 | Feder Julie B | Chief Financial Officer | Sell | 25,131 | $12.03 | $302.4K | 0 |
| Oct 16, 2024 | Plavsic Mark | Chief Technology Officer | Sell | 7,383 | $9.85 | $72.7K | 0 |
| Jan 23, 2024 | de los Pinos Elisabet | See Remarks | Sell | 15,853 | $7.64 | $121.1K | 0 |
| Jan 23, 2024 | Feder Julie B | Chief Financial Officer | Sell | 6,609 | $7.64 | $50.5K | 0 |
| Nov 7, 2023 | Johnson David Michael | Director | Buy | 142,601 | $7.19 | $1.02M | 0 |
| Nov 6, 2023 | de los Pinos Elisabet | See Remarks | Sell | 7,449 | $12.03 | $89.6K | 0 |
| Nov 6, 2023 | Feder Julie B | Chief Financial Officer | Sell | 3,900 | $12.07 | $47.1K | 0 |
| Oct 30, 2023 | de los Pinos Elisabet | See Remarks | Sell | 9,586 | $6.83 | $65.5K | 0 |
| Oct 30, 2023 | Feder Julie B | Chief Financial Officer | Sell | 3,385 | $6.82 | $23.1K | 0 |
| Oct 3, 2023 | Johnson David Michael | Director | Buy | 20,066 | $8.38 | $168.2K | 0 |
| Jan 5, 2023 | Johnson David Michael | Director | Buy | 2,000 | $10.41 | $20.8K | 0 |
| Dec 28, 2022 | Johnson David Michael | Director | Buy | 2,000 | $9.75 | $19.5K | 0 |
| Dec 1, 2022 | Johnson David Michael | Director | Buy | 5,000 | $12.37 | $61.9K | 0 |
| Oct 31, 2022 | de los Pinos Elisabet | See Remarks | Sell | 5,706 | $12.46 | $71.1K | 0 |
| Oct 31, 2022 | De Rosch Mark | Chief Operating Officer | Sell | 1,115 | $12.46 | $13.9K | 0 |
| Oct 31, 2022 | Feder Julie B | Chief Financial Officer | Sell | 2,015 | $12.45 | $25.1K | 0 |
| Oct 31, 2022 | Rich Cadmus | See Remarks | Sell | 1,672 | $12.45 | $20.8K | 0 |
| Jun 10, 2022 | Johnson David Michael | Director | Buy | 40,000 | $14.33 | $573.3K | 0 |
AURA Insider Buying Activity
The following table shows recent insider purchases of Aura Biosciences, Inc. (AURA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 16, 2025 | Gibney Anthony S | See Remarks | Buy | 50,000 | $4.90 | $245.0K | 0 |
| May 16, 2025 | Johnson David Michael | Director | Buy | 20,000 | $4.90 | $98.0K | 0 |
| Nov 7, 2023 | Johnson David Michael | Director | Buy | 142,601 | $7.19 | $1.02M | 0 |
| Oct 3, 2023 | Johnson David Michael | Director | Buy | 20,066 | $8.38 | $168.2K | 0 |
| Jan 5, 2023 | Johnson David Michael | Director | Buy | 2,000 | $10.41 | $20.8K | 0 |
| Dec 28, 2022 | Johnson David Michael | Director | Buy | 2,000 | $9.75 | $19.5K | 0 |
| Dec 1, 2022 | Johnson David Michael | Director | Buy | 5,000 | $12.37 | $61.9K | 0 |
| Jun 10, 2022 | Johnson David Michael | Director | Buy | 40,000 | $14.33 | $573.3K | 0 |
AURA Insider Selling Activity
The following table shows recent insider sales of Aura Biosciences, Inc. (AURA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | de los Pinos Elisabet | See Remarks | Sell | 47,648 | $5.06 | $241.1K | 0 |
| Feb 17, 2026 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 8,549 | $5.06 | $43.3K | 0 |
| Feb 17, 2026 | Hopkins Janet Jill | Chief Medical Officer | Sell | 20,401 | $5.06 | $103.2K | 0 |
| Feb 17, 2026 | Kilroy Conor | See Remarks | Sell | 12,079 | $5.05 | $61.0K | 0 |
| Feb 17, 2026 | Plavsic Mark | Chief Technology Officer | Sell | 15,890 | $5.05 | $80.2K | 0 |
| Jan 20, 2026 | de los Pinos Elisabet | See Remarks | Sell | 16,928 | $4.86 | $82.3K | 0 |
| Jan 20, 2026 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 1,581 | $4.86 | $7.7K | 0 |
| Nov 17, 2025 | Hopkins Janet Jill | Chief Medical Officer | Sell | 17,109 | $5.42 | $92.7K | 0 |
| Oct 29, 2025 | de los Pinos Elisabet | See Remarks | Sell | 9,049 | $6.35 | $57.5K | 0 |
| Oct 29, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 896 | $6.35 | $5.7K | 0 |
| Oct 16, 2025 | Plavsic Mark | Chief Technology Officer | Sell | 12,169 | $6.35 | $77.3K | 0 |
| Aug 18, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 7,722 | $6.70 | $51.7K | 0 |
| Jun 2, 2025 | de los Pinos Elisabet | See Remarks | Sell | 9,948 | $6.16 | $61.3K | 0 |
| May 16, 2025 | Gibney Anthony S | See Remarks | Sell | 1,519 | $5.15 | $7.8K | 0 |
| Apr 16, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 897 | $5.49 | $4.9K | 0 |
| Apr 16, 2025 | Kilroy Conor | See Remarks | Sell | 7,162 | $5.49 | $39.3K | 0 |
| Feb 18, 2025 | de los Pinos Elisabet | See Remarks | Sell | 20,221 | $7.75 | $156.8K | 0 |
| Feb 18, 2025 | Elazzouzi Amy | Senior Vice President, Finance | Sell | 1,404 | $7.75 | $10.9K | 0 |
| Feb 18, 2025 | Hopkins Janet Jill | Chief Medical Officer | Sell | 2,534 | $7.75 | $19.6K | 0 |
| Feb 18, 2025 | Plavsic Mark | Chief Technology Officer | Sell | 2,151 | $7.75 | $16.7K | 0 |
| Jan 21, 2025 | de los Pinos Elisabet | See Remarks | Sell | 15,955 | $7.67 | $122.4K | 0 |
| Jan 21, 2025 | Elazzouzi Amy | Vice President, Finance | Sell | 1,001 | $7.67 | $7.7K | 0 |
| Nov 18, 2024 | Hopkins Janet Jill | Chief Medical Officer | Sell | 11,822 | $9.36 | $110.7K | 0 |
| Oct 29, 2024 | de los Pinos Elisabet | See Remarks | Sell | 9,200 | $10.74 | $98.8K | 0 |
| Oct 29, 2024 | Elazzouzi Amy | Vice President, Finance | Sell | 553 | $10.74 | $5.9K | 0 |
| Oct 18, 2024 | de los Pinos Elisabet | See Remarks | Sell | 24,992 | $12.04 | $300.8K | 0 |
| Oct 18, 2024 | Feder Julie B | Chief Financial Officer | Sell | 25,131 | $12.03 | $302.4K | 0 |
| Oct 16, 2024 | Plavsic Mark | Chief Technology Officer | Sell | 7,383 | $9.85 | $72.7K | 0 |
| Jan 23, 2024 | de los Pinos Elisabet | See Remarks | Sell | 15,853 | $7.64 | $121.1K | 0 |
| Jan 23, 2024 | Feder Julie B | Chief Financial Officer | Sell | 6,609 | $7.64 | $50.5K | 0 |
| Nov 6, 2023 | de los Pinos Elisabet | See Remarks | Sell | 7,449 | $12.03 | $89.6K | 0 |
| Nov 6, 2023 | Feder Julie B | Chief Financial Officer | Sell | 3,900 | $12.07 | $47.1K | 0 |
| Oct 30, 2023 | de los Pinos Elisabet | See Remarks | Sell | 9,586 | $6.83 | $65.5K | 0 |
| Oct 30, 2023 | Feder Julie B | Chief Financial Officer | Sell | 3,385 | $6.82 | $23.1K | 0 |
| Oct 31, 2022 | de los Pinos Elisabet | See Remarks | Sell | 5,706 | $12.46 | $71.1K | 0 |
| Oct 31, 2022 | De Rosch Mark | Chief Operating Officer | Sell | 1,115 | $12.46 | $13.9K | 0 |
| Oct 31, 2022 | Feder Julie B | Chief Financial Officer | Sell | 2,015 | $12.45 | $25.1K | 0 |
| Oct 31, 2022 | Rich Cadmus | See Remarks | Sell | 1,672 | $12.45 | $20.8K | 0 |
AURA Insiders
Similar Stocks to AURA
VRTX
Vertex Pharmaceuticals Incorporated
$458.39+1.50%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$739.88-0.56%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$310.89-1.27%
$42.07B
INSM
Insmed Incorporated
$143.59+0.62%
$30.07B
UTHR
United Therapeutics Corporation
$528.14-0.42%
$23.50B
MRNA
Moderna, Inc.
$52.36-0.21%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.73-0.29%
$20.08B
RPRX
Royalty Pharma plc
$45.69-0.24%
$19.56B